NEW
Font size
WorksheetsACLASTA_AUGUST
Total questions: 20
Worksheet time: 3600secs
What is the composition of Aclasta?
Amoxicillin 500mg
Sildenafil 50mg
Denusomab
Zolendronic Acid
What is the drug classification of Aclasta?
Anti – Diuretic
Antibiotic
Bisphosphonate or n-BPs or Nitrogen-containing bisphosphonate
Anti- epileptic
What is the formulation of Aclasta?
5mg/100mL Solution for Intravenous Infusion
4mg/100mL Solution for Intravenous Infusion
10mg/100mL Solution for Intravenous Infusion
15mg/100mL Solution for Intravenous Infusion
Mode of Action of Aclasta.
It inhibits osteoclast activity, increasing resorption and turnover thereby leading to increased bone mass.
It inhibits osteoclast activity, reduces resorption and turnover thereby leading to decrease bone mass.
It inhibits osteoclast activity, reduces resorption and turnover thereby leading to increased bone mass.
It inhibits osteoclast activity, reduces resorption and turnover thereby leading to increased bone density.
What is the indication of Aclasta?
Prevention of post-menopausal osteoporosis
Treatment of osteoporosis
Treatment of post-menopausal osteoporosis
Treatment and prevention of post-menopausal osteoporosis & glucocorticoid-induced osteoporosis.
What is the dosage of Aclasta?
5mg Once a Month via IV Infusion
5mg twice a Year via IV Infusion
5mg Once a Year via IV Infusion
5mg Once a Year via IM
What is the packaging of Aclasta?
Infusion solution of 5mg/100 mL per Vial
Infusion solution of 4mg/100 mL per Vial
Infusion solution of 5mg/50 mL per Vial
Infusion solution of 5mg/10 mL per Vial
What is a systemic skeletal-disease characterized by low bone density and micro architectural deterioration of bone tissue with consequent increase in bone fragility?
Menopause
Andropause
Osteoporosis
Paget’s disease
What are the side effects of Aclasta?
Headache
Pain in Extremities
Flu-like symptoms
All options are correct
What are the contraindications of Aclasta?
Hypocalcemia
Pt w/ Creatinine clearance of >35 mL/min
Pregnancy and lactation
All options are correct
What is the price of Aclasta?
24,848.00
26,730.00
21,000.00
19.000.00
Is Aclasta indicated for paget’s disease?
YES
NO
Maybe
No comment
All bisphosphonates are eliminated from the human body by:
Hepatic Clearance
Renal excretion
Sweat glands
Tears
Treatment with intravenous bisphosphonates, including zoledronic acid, has been associated with renal impairment manifested as deterioration in renal function (i.e. increased serum creatinine) and in rare cases acute renal failure.
True
False
Creatinine clearance should never be measured before each zoledronic acid dose
True
False
In the Horizon PFT, Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI],0.24 to 0.38)
True
False
The study design of Horizon PFT is:
Double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months;the patients were followed until 36 months.
Double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 3 months, and at 6 months;the patients were followed until 12 months.
Double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 30-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months;the patients were followed until 36 months.
Double-blind, placebo-controlled trial, 5889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 18 months;the patients were followed until 24 months.
Identify the primary objectives of Horizon PFT.
A.Incidence of hip fxs
B. Incidence of new vertebral fxs
A&B
None of the options are correct
Identify the results of the Horizon PFT:
A. Reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acidgroup vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83).
B. Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons).
C. None of the options are correct
D. A&B
What is the message of our first RTE for Aclasta?
Effective treatment for Osteoporosis
Compliance is Key
Affordability and Quality
Safety is paramount
